argenx NV ADR (ARGX)vsLENZ Therapeutics Inc (LENZ)
ARGX
argenx NV ADR
$916.80
+5.82%
HEALTHCARE · Cap: $58.73B
LENZ
LENZ Therapeutics Inc
$5.90
-2.64%
HEALTHCARE · Cap: $181.54M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 22495% more annual revenue ($4.74B vs $20.99M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
LENZ
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.9%
Fair Value
$2191.36
Current Price
$916.80
$1274.56 discount
Intrinsic value data unavailable for LENZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 193.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : LENZ
The strongest argument for LENZ centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 41.7x leaves little room for execution misses.
Bear Case : LENZ
The primary concerns for LENZ are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while LENZ is a value play — different risk/reward profiles.
LENZ carries more volatility with a beta of 1.47 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (71/100 vs 31/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
LENZ Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
LENZ Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for neurological disorders, with an emphasis on addressing significant unmet needs in the central nervous system (CNS). Leveraging advanced drug formulation and delivery technologies, the company boasts a robust pipeline of proprietary assets designed to improve patient outcomes. With strategic partnerships and a strong commitment to rigorous clinical research, LENZ is well-positioned for substantial growth and aims to establish itself as a key player in the biopharmaceutical sector, capitalizing on emerging opportunities within the evolving healthcare market.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?